Table 2 Analysis of outcomes
| Â | Treatment as usual | Medication review tool | Coefficient or OR (95Â % CI) | ||
|---|---|---|---|---|---|
| Â | Baseline | Follow-up | Baseline | Follow-up | Â |
Outcome | Â | Â | Â | Â | Â |
Decision Self Efficacy Scale (mean, SD) | 29 (9) | 32 (10) | 29 (10) | 30 (9) | -4.16 (-9.81, 1.49) |
Drug Attitude Inventory (mean, SD) | 5 (4) | 3 (4) | 5 (4) | 5 (3) | 1.65 (-0.09, 3.40) |
LUNSERS (mean, SD) | 38 (23) | 28 (19) | 38 (23) | 30 (20) | -0.42 (-8.12, 7.29) |
Brief PANSS (mean, SD) | 18 (7) | 16 (7) | 17 (7) | 16 (6) | 0.13 (-2.21, 2.48) |
Client Satisfaction Questionnaire (mean, SD) | Â | 28 (5) | Â | 27 (5) | -0.29 (-3.04, 2.45)a |
Medication Adherence Questionnaire (median, IQR) | 0 (0, 1) | 1 (0, 1) | 0 (0, 0) | 0 (0, 1) | -0.44 (-0.76, -0.11) |
2 or more antipsychotics taken (n/N, %) | 7/29 (24) | 7/24 (29) | 4/31 (13) | 7/26 (27) | 0.89 (0.26, 3.08)b |
Dose (chlorpromazine equivalents) (median, IQR) | 400 (200, 600) | 350 (200, 648) | 250 (132, 400) | 292 (200, 462) | -26.02 (-97.23, 45.20) |
Change in chlorpromazine equivalent baseline-FU (median, IQR) | Â | 0 (0, 50) | Â | 0 (-64, 65) | 3.33 (-78.12, 84.79) |